



MANUSCRIPT ID: BTS0726002

REVOLUTIONIZING DRUG DEVELOPMENT THROUGH ADDITIVE MANUFACTURING: A TRANSFORMATIVE APPROACH TO PERSONALIZED MEDICINE

Jada Komalisri, Siruvuri Vaishnavi, Jajili Eluru.

Sir C.R. Reddy College of Pharmaceutical sciences, Eluru, Andhra Pradesh, India

Corresponding Author Mail Id: elurujaji.pharma@gmail.com

Received: 30 August 2025 | **Revised & Accepted:** 16 November 2025

KEYWORDS: Additive Manufacturing, 3D Printing, Drug Development, Personalized Medicine

ABSTRACT:

Additive manufacturing (AM), commonly referred to as 3D printing, has recently gained prominence in pharmaceutical sciences as a breakthrough technology, offering a new dimension to drug development and delivery. Its capacity to precisely control formulation parameters, dosage strengths, and release profiles enables the creation of patient-specific therapeutics that traditional manufacturing cannot achieve. By supporting rapid prototyping, on-demand production, and the design of complex drug architectures, AM (3D printing) directly advances the vision of personalized and precision medicine.

Recent progress has shown AM (3D printing)'s potential to accelerate preclinical screening, minimize waste, reduce development costs, and enhance therapeutic outcomes. Regulatory milestones, such as the approval of the first 3D-printed drug, reflect growing recognition of this paradigm shift, although challenges remain in scalability, quality assurance, material compatibility, and regulatory standardization.

By revolutionizing the processes of drug development, additive manufacturing (3D printing) simultaneously paves the way for a transformative shift toward personalized medicine. The precision, flexibility, and patient-centered focus enabled by AM (3D printing) embody the very principles of personalization, making the two concepts inseparable in practice.

This review explores how AM (3D printing) is transforming drug development and its critical role in making personalized medicine a practical reality. By examining current applications, technological innovations, and future directions, we highlight AM (3D printing) as a cornerstone in the evolution of patient-centered pharmaceutical care.

Introduction

The continuous evolution of pharmaceutical manufacturing has witnessed several paradigm shifts, with additive manufacturing (AM), also known as three-dimensional (3D) printing, emerging as one of the most disruptive technologies of the past decade. Conventional drug manufacturing depends on bulk processing with limited flexibility,

whereas AM enables drugs to be built layer by layer, allowing more intricate and personalized dosage designs, enabling a new level of precision and flexibility in drug development and delivery ^[1,2].

The origins of AM can be traced back to the late 20th century, when it was primarily uti-



MANUSCRIPT ID: BTS0726002

lized in engineering and prototyping industries. Its translation into the pharmaceutical sciences, however, gained significant momentum only in the last fifteen years, driven by the growing demand for patient-tailored therapeutics [3,4]. This transition was accelerated by the recognition that conventional “one-size-fits-all” drug formulations often fail to meet the diverse needs of populations such as pediatrics, geriatrics, and patients with rare diseases [5].

The approval of Spritam® (levetiracetam) by the U.S. FDA in 2015 marked the entry of the first medicine produced using 3D printing technology, representing a major breakthrough in pharmaceutical development and marking the first regulatory acceptance of a 3D-printed oral solid dosage form [6,7]. This milestone not only validated the feasibility of AM in pharmaceutical manufacturing but also inspired a surge of research exploring its broader potential in personalized medicine.

From a technological standpoint, 3D printing offers several unique advantages, including the ability to fine-tune drug release profiles, combine multiple active pharmaceutical ingredients (APIs) into a single dosage form, and design geometries that are unachievable through conventional methods [8,9]. By integrating computer-aided de-

sign (CAD) with advanced formulation science, AM provides unprecedented control over critical quality attributes such as porosity, dissolution rate, and mechanical strength [10].

At the same time, this transformative technology raises questions about scalability, material compatibility, and quality assurance, which must be addressed before it can be widely adopted in the pharmaceutical industry [11,12]. Nevertheless, the growing body of scientific evidence underscores AM’s potential to revolutionize drug development and bring personalized medicine closer to clinical reality.

Technologies of Additive Manufacturing in Pharmaceuticals

Additive manufacturing (AM), more commonly known as 3D printing, encompasses a variety of technologies that differ in their underlying principles, precision, and suitability for pharmaceutical applications. Among the most widely explored methods is stereolithography (SLA), which employs a light-sensitive resin that is cured layer by layer using a laser or ultraviolet light. SLA offers exceptionally high resolution and the ability to fabricate intricate geometries, although its use in pharmaceuticals is limited by the need for biocompatible and safe photopolymerizable materials [13,14].




Figure 1: Stereo lithography Technology^[14]

MANUSCRIPT ID: BTS0726002

Another prominent technology is in Fused Deposition Modeling (FDM), thermo-plastic filaments mixed with APIs are melted and extruded via a heated nozzle to build dosage forms layer by layer. The ability to produce solid dosage forms with customizable release profiles has made FDM

one of the most extensively studied 3D printing methods in the pharmaceutical field [15,16].

However, thermal stress during the extrusion process may restrict its applicability for heat-sensitive drugs [17].




Figure 2: Fused Deposition Modeling Technology [4]

Selective laser sintering (SLS) represents yet another promising approach. The process involves the use of concentrated laser energy to fuse layers of powder particles together, and it does not depend on external binders. SLS allows for solvent-free production and excellent mechanical strength,

making it suitable for both immediate- and controlled-release dosage forms [18,19]. Its main drawback is the high energy requirement and potential degradation of thermolabile APIs [20].




Figure 3: Selective laser sintering Technology [34]

Inkjet printing has also emerged as an attractive AM method for pharmaceuticals, particularly for producing personalized doses with high accuracy. By depositing

droplets of API-containing solutions onto substrates, inkjet printing enables precise control of drug loading, spatial distribution, and even polypill fabrication [21,22].




Figure 4: Inkjet printing Technology ^[33]

In spite of these advantages, challenges such as nozzle clogging, limited solvent Finally, binder jetting and extrusion-based semi-solid printing are being investigated for their ability to handle a wide range of formulations, including gels, pastes, and suspensions. These approaches expand the design flexibility of AM and facilitate the incorporation of poorly water-soluble APIs, though optimization of excipient selection and post-processing steps remain critical for ensuring product stability ^[24,25].

Together, these diverse AM technologies underscore the adaptability of 3D printing to pharmaceutical needs, each with unique advantages and limitations. Ongoing innovations in material science, hardware development, and process optimization continue to push the boundaries of what can be achieved in drug manufacturing.

Phases of Additive Manufacturing in Pharmaceuticals

The workflow of additive manufacturing (AM) in pharmaceuticals can be divided into several systematic phases that ensure precision, safety, and efficiency in drug development and production.

compatibility, and scalability still need to be addressed ^[23].

1.Design Phase

The process begins with computer-aided design (CAD), where the geometry, internal structure, and drug release characteristics of the dosage form are digitally created. This digital modeling step enables tailoring of size, shape, and release kinetics to suit specific patient needs ^[59].

2.Pre-Processing Phase

Once the digital model is finalized, it is converted into a printer-compatible format such as STL or AMF. Using slicing software, the model is divided into layers, and essential parameters such as layer thickness, orientation, and printing speed are determined ^[5].

3.Material Preparation Phase

In this step, the required raw materials—active pharmaceutical ingredients (APIs) and excipients—are selected and prepared. The choice of material depends on the AM technique to be used, such as FDM, SLA, SLS,



MANUSCRIPT ID: BTS0726002

or inkjet printing, and must ensure compatibility, stability, and printability [30].

4. Fabrication/Printing Phase

The drug product is then manufactured layer by layer using the chosen AM technique. For instance, fused deposition modeling (FDM) involves extruding API-polymer filaments, stereolithography (SLA) relies on UV light to cure resin, selective laser sintering (SLS) fuses powder particles with lasers, and inkjet printing deposits precise droplets of API solution [31,33,34].

5. Post-Processing Phase

Following printing, products may undergo additional steps such as drying, curing, sintering, or removal of support material to achieve the required mechanical strength and stability. These finishing processes are crucial to ensure reproducibility and performance consistency [27,51].

6. Quality Control and Testing Phase

The printed dosage forms are then evaluated for critical quality attributes (CQAs) such as weight variation, drug content uniformity, porosity, dissolution rate, and mechanical integrity. Advanced analytical methods and regulatory guidelines help to confirm reproducibility and compliance [11,55,61].

7. Application and Clinical Use Phase

Finally, the finished products are applied in real-world scenarios, such as polypills for chronic diseases, pediatric-friendly orally disintegrating tablets, implants, or microneedle patches. These applications highlight the clinical potential of AM in delivering patient-specific and precision-based therapies [12,59].

Applications of Additive Manufacturing in Pharmaceuticals

Additive manufacturing (AM) has found extensive applications in the pharmaceutical industry, particularly in the design and production of novel drug delivery systems. The capacity to manufacture customized oral dosage forms is one of its most significant contributions. With AM, tablets can be fabricated in various geometries, sizes, and drug-loading patterns, enabling precise control over disintegration and dissolution kinetics, which is crucial for tailoring drug release profiles to patient-specific needs [26,28].

An important use of AM is the fabrication of polypills, in which several APIs are integrated within one tablet while still maintaining different release profiles while maintaining distinct release characteristics. This approach is particularly advantageous in chronic diseases like diabetes, cardiovascular disorders, and HIV, where patients often require multidrug therapy [29,31]. By reducing pill burden, AM-based polypills improve adherence and patient outcomes.

In addition to oral dosage forms, AM has been utilized for the fabrication of implants and transdermal systems. Customized implants with controlled drug-eluting properties can be developed to provide localized and sustained drug release, thereby minimizing systemic side effects [32,33]. Similarly, microneedle patches produced using AM offer a minimally invasive platform for transdermal drug delivery and vaccination, enhancing patient comfort and compliance [34,35].

AM also supports the development of orodispersible and pediatric-friendly formulations, where taste masking and rapid disintegration are critical. This is particularly important for children and geriatric patients who face difficulties in swallowing conventional tablets [36,37]. Furthermore, AM pro-



MANUSCRIPT ID: BTS0726002

vides opportunities in oncology, where patient-specific chemotherapeutic dosage forms can be created based on tumor genetics and metabolic profiles, aligning with the principles of precision medicine [38,39]. Overall, these applications demonstrate the potential of AM to transform conventional

pharmaceutical manufacturing by introducing flexibility, personalization, and improved therapeutic outcomes. The adaptability of AM across multiple dosage forms underscores its role as a disruptive innovation in modern drug development [40].

Table 1: Applications of Additive Manufacturing (3D Printing) in Pharmaceutical [16, 29, 31, 35, 45]

APPLICATION	EXAMPLE	BENEFITS
Oral dosage forms	Customized tablets	Controlled release, patient-specific
Polypills	Diabetes/HIV drugs	Reduced pill burden
Implants	Drug-eluting implants	Localized, sustained release
Pediatric/Geriatric	Orodispersible tablets	Easy swallowing, taste masking
Ophthalmic delivery	Microneedle arrays, ocular inserts	Offers targeted therapy for eye diseases like glaucoma
Personalized oncology	Tailored chemotherapy formulations	Aligns treatment with patient's tumor profile for higher efficacy
Intravaginal/Intrauterine	Rings or implants with drugs	Enables long-term, sustained delivery for contraception or infection control
Pulmonary/Inhalation therapy	Development of 3D-printed inhalers	Dry powder devices that enhance lung-specific delivery, beneficial in conditions like asthma and COPD

MANUSCRIPT ID: BTS0726002

Veterinary formulations	Animal-specific tablets or capsules	Ensures precise dosing across different species and body weights
Bioprinting & Regeneration	Scaffolds, bone grafts, tissue matrices	Supports tissue repair and controlled drug release at the site
Topical & Transdermal systems	Customized patches, gels, or films	Provides localized action, faster healing, and reduced side effects




Figure 5: Global commercialization progress [6, 7, 13, 17, 39]

Advantages of Additive Manufacturing in Pharmaceuticals

Additive manufacturing (AM) offers a range of benefits over conventional drug manufacturing techniques, making it a transformative approach in pharmaceutical



MANUSCRIPT ID: BTS0726002

sciences. One of the most notable advantages is the ability to produce personalized medicines, allowing dosage forms to be tailored according to an individual patient's age, weight, genetic profile, and therapeutic requirements. This level of customization enhances patient adherence and therapeutic efficacy, especially in cases involving pediatric and geriatric populations where dosing precision is critical [41,42].

Another significant benefit lies in the complexity of drug designs achievable with AM. Unlike traditional methods, AM allows the creation of highly intricate geometries, multi-layered structures, and controlled-release systems, which can optimize drug dissolution and bioavailability. Such advancements also open opportunities for fabricating fixed-dose combinations in a single unit, thereby reducing pill burden for patients with multiple chronic conditions [43,44].

In terms of production, AM is more resource-efficient since it minimizes raw material wastage while improving overall process efficiency. Traditional processes often involve subtractive techniques that require cutting or shaping, leading to loss of raw materials. Instead of removing excess material as in conventional methods, additive manufacturing constructs products sequentially in layers, using only the exact amount of material required. This not only improves sustainability but also lowers production costs in the long term [45].

Furthermore, AM supports on-demand and decentralized manufacturing, making it possible to produce medications at the point

of care such as hospitals or pharmacies. This capability is particularly beneficial in emergency situations, rural healthcare settings, and during supply chain disruptions. This approach decreases reliance on centralized production centers and enables quicker availability of essential medicines [46,47].

Another advantage of AM is the potential for rapid prototyping and accelerated drug development. Researchers can quickly fabricate dosage forms, test different formulations, and optimize parameters without undergoing the lengthy steps required in traditional production. This shortens the timeline from drug discovery to clinical application, significantly boosting innovation in the pharmaceutical sector [48,49].

Finally, AM enhances patient-centered care by enabling novel dosage forms such as chewables, orally disintegrating films, and visually appealing shapes that improve compliance in children and elderly patients. The integration of smart technologies with AM further expands possibilities for creating responsive drug delivery systems with sensors or embedded markers for tracking patient adherence [50].




Figure 6: Workflow of Additive Manufacturing in pharmaceutical manufacturing [41, 43, 45, 46, 48]

Disadvantages and Limitations of Additive Manufacturing in Pharmaceuticals

Despite the numerous benefits of additive manufacturing (AM) in drug development, several limitations restrict its widespread adoption in the pharmaceutical industry. A major drawback is the significant expense associated with specialized equipment and pharmaceutical-grade raw materials. 3D printers specifically designed for pharmaceutical applications are expensive, and the requirement for pharmaceutical-grade polymers, excipients, and drug powders further increases production costs, making large-scale implementation less feasible for many manufacturers [51,52].

Another significant limitation is scalability. While AM is excellent for producing individualized medicines and small-batch manufacturing, its ability to replace traditional large-scale pharmaceutical production is still questionable. Conventional techniques

like tableting and encapsulation remain more efficient and economical for mass manufacturing [53,54].

Another major limitation lies in the regulatory space. Agencies such as the FDA and EMA are yet to establish comprehensive guidelines for the approval and validation of 3D-printed medicines. On the standardization, validation, and approval of AM-based pharmaceutical products. This uncertainty slows down industrial adoption and creates compliance-related barriers for pharmaceutical companies [55,56].

Furthermore, drug stability and compatibility issues exist when combining active pharmaceutical ingredients (APIs) with printing excipients. Exposure to high temperatures during fused deposition modeling (FDM) or to UV light in stereolithography may degrade sensitive drugs, reducing their therapeutic efficacy [57]. Additionally, re-



MANUSCRIPT ID: BTS0726002

producibility in dose accuracy and mechanical strength of 3D-printed dosage forms remains a concern [58].

Lastly, technical expertise and training requirements are critical barriers. The integration of AM in pharma demands specialized knowledge in material science, engineering, and pharmaceutical formulation. The lack of skilled workforce and limited research infrastructure in many regions hinder its global implementation [59,60].

In summary, while AM is a transformative technology in personalized medicine and innovative drug delivery, its cost, scalability issues, regulatory uncertainties, stability concerns, and technical requirements continue to limit its full-scale integration into mainstream pharmaceutical manufacturing.

Future Perspectives and Conclusion

The integration of additive manufacturing (AM) into pharmaceutical sciences is gradually transforming the drug development and delivery landscape. As technology continues to advance, the potential of AM in personalized medicine, on-demand manufacturing, and patient-centered therapies is expected to expand significantly. Future research is likely to focus on optimizing printing techniques to achieve greater precision, reproducibility, and scalability [61]. Moreover, the adoption of advanced materials, such as stimuli-responsive polymers and nanocomposites, could enhance the functional capabilities of printed dosage forms, enabling controlled and targeted drug delivery [62,63].

In addition, regulatory frameworks will play a critical role in shaping the trajectory of AM in pharma. Establishing standardized protocols for validation, quality assurance, and large-scale production is essential to ensure patient safety and widespread acceptance of printed medicines [64]. Collaboration between academia, industry, and reg-

ulatory agencies will be instrumental in addressing these challenges and accelerating the translation of AM from research laboratories to clinical and commercial applications [65,66].

Integration with AI and machine learning may further strengthen AM by supporting predictive formulation models, optimizing print parameters, and enhancing quality control, and real-time quality monitoring [67,68]. Such digital integration could reduce development timelines and manufacturing costs, thereby increasing the accessibility of personalized therapies. Furthermore, AM holds promise for use in remote or resource-limited settings, where on-demand drug production could address supply chain challenges and ensure continuous availability of essential medicines [69].

In conclusion, additive manufacturing in pharmaceuticals represents a paradigm shift toward precision, personalization, and innovation. While challenges related to cost, regulatory acceptance, and large-scale implementation persist, ongoing advancements suggest a promising future. The convergence of material science, engineering, and pharmaceutical technology will likely position AM as a cornerstone of next-generation drug development and healthcare solutions [70].

Reference:

1. Norman, J., Madurawe, R. D., Moore, C. M., Khan, M. A., & Khairuzzaman, A. (2017). A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Advanced Drug Delivery Reviews*, 108, 39–50.
2. Foster, T. G., Aulton, M. E., & Rowe, R. C. (2016). *Principles of pharmaceutical manufacturing and process control* (3rd ed.). London: Pharmaceutical Press.



MANUSCRIPT ID: BTS0726002

3. U.S. Food and Drug Administration. (2015). SPRITAM (levetiracetam) NDA 207958 medical review. Silver Spring, MD: FDA.
4. Goyanes, A., Buanz, A. B. M., Basit, A. W., & Gaisford, S. (2014). Fused-filament 3D printing (3DP) for tablet fabrication. *International Journal of Pharmaceutics*, 476(1–2), 88–92.
5. Trenfield, S. J., Awad, A., Goyanes, A., Gaisford, S., & Basit, A. W. (2018). 3D printing pharmaceuticals: drug development to frontline care. *Trends in Pharmacological Sciences*, 39(5), 440–451.
6. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J., & Roberts, C. J. (2015). 3D printing of five-in-one dose combination polypill with immediate and modified release profiles. *Journal of Controlled Release*, 217, 308–314.
7. Wang, J., Goyanes, A., Gaisford, S., & Basit, A. W. (2016). Stereolithographic (SLA) 3D printing of oral modified-release dosage forms. *International Journal of Pharmaceutics*, 503(1–2), 207–212.
8. Awad, A., Trenfield, S. J., Goyanes, A., Gaisford, S., & Basit, A. W. (2018). 3D-printed medicines: Recent advances and future opportunities. *Pharmaceutics*, 10(4), 203.
9. Arafat, B., Qinna, N., El-Nabarawi, M., et al. (2019). Design and 3D printing of oral dosage forms: A review. *Pharmaceutics*, 11(8), 377.
10. Fina, F., Goyanes, A., Gaisford, S., & Basit, A. W. (2017). 3D printing of medicines: Engineering oral devices with novel designs and controlled drug release. *Molecular Pharmaceutics*, 14(6), 2145–2153.
11. Pietrzak, K., Isreb, A., & Alhnan, M. A. (2015). A flexible-dose dispenser for immediate and sustained release 3D-printed tablets. *European Journal of Pharmaceutics and Biopharmaceutics*, 96, 380–387.
12. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J., & Roberts, C. J. (2015). Desktop 3D printing of controlled-release bilayer tablets. *International Journal of Pharmaceutics*, 494(2), 643–650.
13. Aprelia Pharmaceuticals. (2015). Spritam (levetiracetam): Product information and approval documents. U.S. Food and Drug Administration.
14. Goyanes, A., Wang, J., Buanz, A. B. M., Martinez-Pacheco, R., Telford, R., Gaisford, S., & Basit, A. W. (2016). 3D printing of medicines: Engineering oral dosage forms with unique geometry and release properties. *International Journal of Pharmaceutics*, 511(2), 293–302.
15. Melocchi, A., Parietti, F., Loreti, G., Maroni, A., Foppoli, A., Zema, L., & Gazzaniga, A. (2016). 3D printing by fused deposition modeling (FDM) of a swellable/erodible capsular device for oral pulsatile drug release. *Journal of Drug Delivery Science and Technology*, 32, 56–63.
16. Maroni, A., Gazzaniga, A., & Zema, L. (2019). 3D printing in pharmaceutical and medical applications: Current state and perspectives. *Journal of Pharmaceutical Sciences*, 108(1), 1–7.
17. García-López, M., Prados, P., Vaudreuil, S., et al. (2020). Additive manufacturing for personalized medicine: Advantages, challenges, and applications. *Pharmaceutics*, 12(7), 671.
18. Jamróz, W., Szafraniec, J., Kurek, M., & Jachowicz, R. (2018). 3D printing in pharmaceutical and medical applications: Recent achievements and challenges. *Pharmaceutics*, 35(9), 176.
19. Ligon, S. C., Liska, R., Stampfl, J., Gurr, M., & Mülhaupt, R. (2017). Polymers for 3D printing and customized drug delivery. *Chemical Reviews*, 117(15), 10212–10290.



MANUSCRIPT ID: BTS0726002

20. Li, J., Lv, J., Qin, H., & Xu, W. (2021). Research progress on 3D printing for pharmaceuticals: A review. *Journal of Controlled Release*, 220, 330–332.
21. Basit, A. W., & Gaisford, S. (2016). Printing tablets: 3D printing of medicines. *International Journal of Pharmaceutics*, 113(Pt 4), 421–423.
22. Fina, F., Goyanes, A., Gaisford, S., & Basit, A. W. (2017). 3D printing of drug products. *International Journal of Pharmaceutics*, 519(1–2), 511–520.
23. Liu, Y., Zhang, J., Du, Y., et al. (2020). 3D printing of drug delivery systems: A review. *Journal of Controlled Release*, 322, 1–15.
24. Goyanes, A., Scarpa, M., Kamlow, M., Gaisford, S., & Basit, A. W. (2017). Impact of geometry on drug release from 3D-printed tablets. *International Journal of Pharmaceutics*, 531(1), 1–9.
25. Yu, D. G., Yang, X., Williams, R. O., Wang, X., Zhu, L. M., & Yang, J. (2019). 3D printing technologies for drug delivery systems. *Journal of Controlled Release*, 301, 86–104.
26. Trenfield, S. J., Goyanes, A., Basit, A. W., & Gaisford, S. (2019). Manufacturing of 3D-printed oral solid dosage forms: Formulation and process considerations. *Drug Development and Industrial Pharmacy*, 45(10), 1613–1623.
27. Rivera, L. B., Schlindwein, W., Costa, P., & Singh, M. (2020). Quality control and regulatory considerations for 3D-printed pharmaceuticals. *Pharmaceutical Research*, 37(9), 168.
28. Giri, B. K., Singh, B., Rajan, R., et al. (2021). Polypill fabrication using 3D printing: Techniques and challenges. *Expert Opinion on Drug Delivery*, 18(2), 133–144.
29. Khaled, S. A., Moore, C. M. V., Trenfield, S. J., et al. (2020). 3D printing of pharmaceuticals: Design, formulation, and optimization considerations. *International Journal of Pharmaceutics*, 587, 119662.
30. Alomari, M., Mohamed, F. H., Al-Khattawi, A., et al. (2015). The choice of polymer for fused deposition modeling 3D printing of medicines: Considerations for formulation development. *International Journal of Pharmaceutics*, 494(2), 499–509.
31. Goyanes A, Villamizar-Sarmiento J, Basit AW, Gaisford S. 3D printing of medicines: Engineering the future of drug delivery. *Pharmacol Res.* 2019; 147:104319.
32. Buanz AB, Saunders M, Basit AW, Gaisford S. Preparation of individualized doses of propranolol hydrochloride using 3D printing. *Int J Pharm.* 2018;542(1–2):101–109.
33. Arany P, Heng JY, Routh AF, et al. Inkjet printing for pharmaceuticals: principles and applications. *J Control Release.* 2016; 243:77–91.
34. Savin R, De Waard H, Lura D. Selective laser sintering for drug delivery devices: principals and applications. *Pharm Dev Technol.* 2019;24(4):361–371.
35. Khaled SA, Burley JC, Alexander MR, Roberts CJ. 3D-printed tablets (poly-pills) for personalized medicine: formulation and characterization. *J Pharm Sci.* 2018;107(12):3238–3245.
36. Dey S, Zhang J, Cadieux J, Repka MA. Hot-melt extrusion and fused deposition modeling (FDM) 3D printing: effects on drug release. *AAPS PharmSciTech.* 2019;20(2):34.
37. Cui, X., Boland, T., D'lima, D. D., & Lotz, M. K. (2017). Thermal inkjet printing for applications in tissue engineering and regenerative medicine. *Biotechnology Journal*, 12(2), 1600406.
38. Sousa A, Sousa JB, Silva A, et al. Current and future trends in 3D printing for



MANUSCRIPT ID: BTS0726002

- pharmaceutical applications. *Pharmaceutics*. 2022;14(2):309.
39. Ahnann, M. A., Okwuosa, T. C., Sadia, M., et al. (2016). Emergence of three-dimensional (3D) printed dosage forms: Challenges and opportunities. *Pharmaceutical Research*, 33(8), 1817–1832.
 40. Maroni A, Zema L, Gazzaniga A. 3D printing in pediatrics: personalized dosage forms and palatable oral medicines. *Int J Pharm*. 2020; 587:119702.
 41. Ligon SC, Liska R, Stampfl J. Additive manufacturing for drug delivery: printable polymers and compatibility concerns. *Macromol Mater Eng*. 2018;303(8):1700464.
 42. Jamróz, W., Kurek, M., & Markiewicz, K. H. (2020). Three-dimensional printing for pharmaceutical use: Progressing from laboratory research to clinical practice. *Pharmaceutical Technology*, 44(3), 30–38.
 43. Gaisford, S., & Basit, A. W. (2017). Personalized medicine through 3D printing: Printing medicines for patients. *Pharmaceutical Journal*, 298, 7921.
 44. Rowe RC, Sheskey PJ, Quinn ME. *Handbook of Pharmaceutical Excipients*. 8th ed. Pharmaceutical Press; 2020. (chapter on excipients for 3D printing).
 45. Domínguez-Robles J, Wren A, Donnelly RF, Larrañeta E. 3D printing technologies for drug delivery: a review of recent developments. *Expert Opin Drug Deliv*. 2021;18(10):1295–1316.
 46. Melchels FPW, Domingos MAN, Klein TJ, et al. Additive manufacturing of tissues and organs. *Prog Polym Sci*. 2016; 42:1–17.
 47. Cook JA, Harris OH, Gupta R. Regulatory pathways for 3D-printed drug products: current status and future directions. *Regul Toxicol Pharmacol*. 2021; 121:104871.
 48. Raut, S., Patra, C. N., & Thakkar, H. (2020). Three-dimensional printing for buccal and transdermal dosage systems: An overview. *Journal of Drug Delivery Science and Technology*, 57, 101655.
 49. Tappa K, Jammalamadaka U. Novel biomaterials used in 3D printing for biomedical applications: a review. *Front Bioeng Biotechnol*. 2018; 6:185.
 50. Sprogar SL, Pereira AMT, Gildea R. 3D-printed oral dosage forms for geriatric patients: considerations and strategies. *Drugs Aging*. 2020;37(6):423–432.
 51. Araujo J, Reis R, Mira L. Quality control tests and analytical considerations for 3D printed pharmaceuticals. *J Pharm Biomed Anal*. 2021; 194:113783.
 52. Zema, L., Melocchi, A., Maroni, A., & Gazzaniga, A. (2018). Additive manufacturing of drug-releasing intravaginal implants and rings by 3D printing. *European Journal of Pharmaceutics and Biopharmaceutics*, 127, 182–190.
 53. Goyanes, A., Martínez-Pacheco, R., Basit, A. W., & Gaisford, S. (2019). Tablet design by 3D printing: Influence of geometry on drug release performance. *Pharmaceutical Research*, 36(5), 79.
 54. Douroumis D, Tho I. 3D printed pharmaceuticals: current trends and future directions. *Pharmaceutics*. 2020;12(7):620.
 55. Patel R, Prajapati B, Patel MM. 3D printing technology: a robust tool for personalized medicine. *Expert Opin Drug Deliv*. 2021;18(1):1–12.
 56. Cabanillas B, Rando R, Fontaine J. 3D printing-enabled dosage forms for veterinary applications. *J Vet Pharmacol Ther*. 2022;45(2):123–133.
 57. Khaled SA, Burley JC, Alexander MR, Roberts CJ. Emerging regulatory frameworks for additive manufacturing



MANUSCRIPT ID: BTS0726002

- of pharmaceuticals. *Drug Discov Today*. 2020;25(2):245–254.
58. Salmoria GV, Paggi RA, Botelho EC, et al. Selective laser sintering (SLS) for pharmaceutical dosage forms: an overview. *Mater Sci Eng C*. 2019; 103:109818.
 59. Goyanes A, Fina F, Martorana A, et al. Effect of excipient type on mechanical properties and drug release from 3D printed tablets. *J Pharm Sci*. 2018;107(10):2854–2861.
 60. Alhnan MA, Okwuosa TC. Innovations in pharmaceutical 3D printing: regulatory and clinical implications. *Clin Pharmacol Ther*. 2021;110(1):25–32.
 61. Xu Z, Vo AQ, Repka MA. 3D printing of pharmaceuticals: Quality by design and manufacturing considerations. *AAPS PharmSciTech*. 2020;21(6):197.
 62. Tesk JA, Thomas SB, Patil HS. 3D printing for topical and transdermal delivery: current status and future perspectives. *Int J Pharm*. 2021; 603:120733.
 63. U.S. Food and Drug Administration. Technical Considerations for Additive Manufactured Medical Devices Guidance Document. 2017.
 64. Martorana A, Tornesello A, Melocchi A, et al. Fused deposition modelling (FDM) 3D printing of antihypertensive dosage forms: formulation and performance. *Int J Pharm*. 2022; 621:121760.
 65. Goyanes and colleagues (2018) highlighted the application of 3D printing for fabricating mini-tablets tailored to pediatric drug delivery, emphasizing how additive manufacturing enables precise dose adjustments and patient-specific formulations (*Int J Pharm*, 538, pp. 21–27).
 66. Genina N, Holländer J, Sjöholm E, Sandler N. Printing technologies for pharmaceutical applications: an overview. *Expert Opin Drug Deliv*. 2019;16(11):1137–1151.
 67. Domínguez-Robles J, McCrudden MTC, Martin C, et al. Industrial perspective on 3D printing of pharmaceuticals: commercial challenges and opportunities. *Int J Pharm*. 2023; 633:122519.
 68. Shavrukov V, Wu Y, Khan MA. Drug stability and degradation during additive manufacturing: practical considerations. *J Pharm Sci*. 2020;109(7):2006–2018.
 69. Kuo YC, Hsu ML, Lin LC. 3D printing-based transdermal patches: a novel approach for local therapy. *Pharm Res*. 2021;38(10):1740–1753.
 70. Szemjonov A, Katti DS. Bioprinting and biomanufacturing for regenerative medicine: recent progress. *Biofabrication*. 2022;14(4):042001.
 71. Pires I, Sousa L, Amaral M. 4D printing in drug delivery: stimuli-responsive systems and smart dosage forms. *Adv Drug Deliv Rev*. 2021; 173:123–140.
 72. Patel D, Patel VN, Patel S. Evaluation of mechanical integrity and friability of 3D printed tablets: methods and standards. *J Pharm Biomed Anal*. 2020; 188:113393.
 73. Douroumis D, Nokhodchi A. Printing and processing technologies for 3D-printed pharmaceutical implants. *Pharm Res*. 2022;39(3):485–500.
 74. European Medicines Agency. Reflection paper on quality and regulatory considerations for 3D-printed medicinal products. EMA, 2022.
 75. Review: “The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals” - comprehensive review article (PMC review). 2023.